scholarly journals Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB)

The Analyst ◽  
2016 ◽  
Vol 141 (2) ◽  
pp. 393-402 ◽  
Author(s):  
Michael Tu ◽  
David Chia ◽  
Fang Wei ◽  
David Wong
Keyword(s):  
Electric Field ◽  
Liquid Biopsy ◽  
Clinical Applications ◽  
Human Cancers ◽  
Oncogenic Mutations ◽  
Analytical Strategies

This paper will review the analytical strategies used to assess oncogenic mutations from biofluid samples. Clinical applications will also be discussed.

Promising member of the short interspersed nuclear elements (Alu elements): mechanisms and clinical applications in human cancers

2019 ◽  
Vol 56 (10) ◽  
pp. 639-645
Author(s):  
Yun Jiang ◽  
Wei Zong ◽  
Shaoqing Ju ◽  
Rongrong Jing ◽  
Ming Cui
Keyword(s):  
Liquid Biopsy ◽  
Repetitive Sequences ◽  
Clinical Applications ◽  
Postoperative Monitoring ◽  
Alu Elements ◽  
The Past ◽  
Human Cancers ◽  
Dna And Rna ◽  
Tumour Diagnosis ◽  
New Perspective

Alu elements are one of most ubiquitous repetitive sequences in human genome, which were considered as the junk DNA in the past. Alu elements have been found to be associated with human diseases including cancers via events such as amplification, insertion, recombination or RNA editing, which provide a new perspective of oncogenesis at both DNA and RNA levels. Due to the prevalent distribution, Alu elements are widely used as target molecule of liquid biopsy. Alu-based cell-free DNA shows feasible application value in tumour diagnosis, postoperative monitoring and adjuvant therapy. In this review, the special tumourigenesis mechanism of Alu elements in human cancers is discussed, and the application of Alu elements in various tumour liquid biopsy is summarised.

Potential clinical applications of circulating cell-free DNA in ovarian cancer patients

2018 ◽  
Vol 20 ◽  
Author(s):  
Ana Barbosa ◽  
Ana Peixoto ◽  
Pedro Pinto ◽  
Manuela Pinheiro ◽  
Manuel R. Teixeira
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Liquid Biopsy ◽  
Clinical Applications ◽  
Epigenetic Alterations ◽  
Cell Free Dna ◽  
Non Invasive ◽  
Free Dna ◽  
Potential Use ◽  
Circulating Cell Free Dna

AbstractCirculating cell-free DNA (cfDNA) consists of small fragments of DNA that circulate freely in the bloodstream. In cancer patients, a fraction of cfDNA is derived from tumour cells, therefore containing the same genetic and epigenetic alterations, and is termed circulating cell-free tumour DNA. The potential use of cfDNA, the so-called ‘liquid biopsy’, as a non-invasive cancer biomarker has recently received a lot of attention. The present review will focus on studies concerning the potential clinical applications of cfDNA in ovarian cancer patients.

scholarly journals Genetic Engineering of Zebrafish in Cancer Research

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2168
Author(s):  
Ludivine Raby ◽  
Pamela Völkel ◽  
Xuefen Le Bourhis ◽  
Pierre-Olivier Angrand
Keyword(s):  
Genetic Alterations ◽  
Therapeutic Strategies ◽  
Molecular Signatures ◽  
Reverse Genetic ◽  
Human Cancers ◽  
Oncogenic Mutations ◽  
Cancer Models ◽  
Conditional Expression ◽  
Cancer Initiation

Zebrafish (Danio rerio) is an excellent model to study a wide diversity of human cancers. In this review, we provide an overview of the genetic and reverse genetic toolbox allowing the generation of zebrafish lines that develop tumors. The large spectrum of genetic tools enables the engineering of zebrafish lines harboring precise genetic alterations found in human patients, the generation of zebrafish carrying somatic or germline inheritable mutations or zebrafish showing conditional expression of the oncogenic mutations. Comparative transcriptomics demonstrate that many of the zebrafish tumors share molecular signatures similar to those found in human cancers. Thus, zebrafish cancer models provide a unique in vivo platform to investigate cancer initiation and progression at the molecular and cellular levels, to identify novel genes involved in tumorigenesis as well as to contemplate new therapeutic strategies.

scholarly journals Monoclonal Antibodies for Cancer Treatment

2021 ◽  
Author(s):  
Annemeri Livinalli ◽  
Taís Freire Galvão
Keyword(s):  
Monoclonal Antibodies ◽  
Cancer Treatment ◽  
Tumor Cells ◽  
Standard Of Care ◽  
Mechanisms Of Action ◽  
Clinical Applications ◽  
Human Cancers ◽  
Therapeutic Monoclonal Antibodies

Therapeutic monoclonal antibodies have emerged in the 1990 decade as an important option for cancer treatment. These molecules have a diverse set of clinically relevant antitumor mechanisms, directly targeting tumor cells. It has been established as “standard of care” for several human cancers. This chapter reviews the use of monoclonal antibodies in oncology and introduces available biosimilars. The requirements for biosimilar antibody development, mechanisms of action and current clinical applications for cancer treatment is also presented.

scholarly journals The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors

2020 ◽  
Vol 65 (1) ◽  
pp. 18-29 ◽  
Author(s):  
Anna Malczewska ◽  
Beata Kos-Kudła ◽  
Mark Kidd ◽  
Ignat Drozdov ◽  
Lisa Bodei ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Liquid Biopsy ◽  
Clinical Applications

Liquid biopsy: novel technologies and clinical applications

2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Natalie Reimers ◽  
Klaus Pantel
Keyword(s):  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Liquid Biopsy ◽  
Clinical Applications ◽  
Novel Technologies ◽  
The Past

Abstract“Liquid biopsy” was introduced as a new diagnostic concept in 2010 for the analysis of circulating tumor cells (CTCs) and has been now extended to material (in particular DNA) released by tumor cells in the peripheral blood of cancer patients. Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients.

Sign in / Sign up

Export Citation Format

Share Document